Home›Companies›Healthcare›Reach Neuro

Reach Neuro, Inc.

Reach Neuro develops implanted spinal-cord stimulation for people seeking to regain shoulder, arm, and hand movement after chronic stroke.

Updated Nov 17, 2026·Latest SEC filing Nov 17, 2026·Suggest an edit

About Reach Neuro

Reach Neuro makes an implanted medical device for stroke survivors who have lost movement in an arm or hand. It delivers small electrical pulses to the spinal cord to help the nervous system restore voluntary control of the shoulder, arm, and hand. Each patient's stimulation is tuned to their needs, and the approach may also serve people with other neurological disorders.

Reach Neuro operates from Providence, Rhode Island. Jennifer Ernst is CEO, and Jordi Parramon is chairman.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 30, 2026Nov 17, 2026$2,000,000fully sold12$166KEquity, Conversion of SAFE'sRule 506(b)Form D ↗
Jul 29, 2022Aug 19, 2022$200,000of $1.5M target1$200KSimple Agreements for Future Equity (SAFEs)Rule 506(b)Form D ↗
Total, two offerings$2,200,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Reach Neuro's Form D filed Nov 17, 2026.

Jennifer Ernst
Jennifer Ernst
CEO and director
First appears on the Form D that Reach Neuro filed on November 17, 2026; on 1 of its 2 filings.
TS
Thorne Sparkman
Director
First appears on the Form D that Reach Neuro filed on November 17, 2026; on 1 of its 2 filings.
Marco Capogrosso
Marco Capogrosso
CSO and director
On every Form D that Reach Neuro has filed: 2 filings, from Aug 19, 2022 to Nov 17, 2026.
Douglas Weber
Douglas Weber
CTO and director
On every Form D that Reach Neuro has filed: 2 filings, from Aug 19, 2022 to Nov 17, 2026.
Jordi Parramon
Jordi Parramon
Chairman
First appears on the Form D that Reach Neuro filed on November 17, 2026; on 1 of its 2 filings.

Earlier filings also listed

  • Peter Gerszten · director and promoter
    Last listed on the Form D that Reach Neuro filed on August 19, 2022; on 1 of its 2 filings.
  • Marc Powell · president and director
    Last listed on the Form D that Reach Neuro filed on August 19, 2022; on 1 of its 2 filings.

Why Investors Backed Reach Neuro

The investment case centers on lasting paralysis after the early stroke-recovery window, when Reach Neuro sees no standard long-term care. Reach Neuro brings early human gains, an NIH-funded clinical program, and FDA Breakthrough Device status to that gap. [2]

“The Breakthrough Device designation is an incredible opportunity to work closely with FDA experts to expedite the clinical translation of the Avantis system.”
Marc Powell · CEO and co-founder, Reach Neuro · FDA Breakthrough Device designation in 2023 [2]

Origin and Team

The company began in 2021 by spinning out research from the University of Pittsburgh and Carnegie Mellon University. Marc Powell served as chief executive officer and co-founder when Avantis received its designation in 2023. Reach Neuro is an alumnus of SOSV's IndieBio startup program. [2]

Product and Technology

Its Avantis implant places an electrode array in the neck portion of the spinal cord. That area contains neurons controlling shoulder, arm, and hand movement. An implanted generator sends small electrical pulses through a plan tuned to each patient. [1][2]

In the first two study participants, grip strength improved 40% and 108%. Joint strength rose by as much as 124%, and reaching was 30% to 40% faster. Participants lifted objects, ate with a fork, and opened a lock. [2]

Early evidence included benefit as late as nine years after stroke, beyond the usual six-month therapy window. Researchers observed some gains lasting one month without stimulation. The approach strengthened muscle activity without unintended movements. [2]

Milestones

Scroll table to see all columns →

DateWhat happenedSourceCoverage
Jun 2026A feasibility trial assessed spinal-cord stimulation for arm movement in people with lasting weakness on one side after a stroke.[1]—
Apr 10, 2023The FDA granted Breakthrough Device designation to Avantis.[2]—
Apr 2023SOSV included Reach Neuro in its 2023 Human Health 100.[1]—
2023The team published the first two trial participants' results in Nature Medicine.[2]—
2023The technology was undergoing an NIH-funded clinical trial with UPMC.[2]—

Market

Reach Neuro estimates that 800,000 people in the United States have a stroke each year, with nearly half developing some lasting paralysis. It also puts the population living with post-stroke disability near 7.5 million. [2]

Reach Neuro sees no standard care for chronic post-stroke paralysis. It links poor access to later therapy with limited evidence of benefit after the first three to six months. [2]

We wrote this summary from public statements by Reach Neuro and its investors. It is not investment advice.

Sources

  1. CompanyReach Neuro company website · linked above ↑
  2. PressReach Neuro FDA Breakthrough Device release
  3. SECReach Neuro Form D, filed 2026-11-17 · linked above ↑
  4. SECReach Neuro Form D, filed 2022-08-19 · linked above ↑
  5. SECReach Neuro, Inc. filing history